Ventas, Inc. (NYSE:VTR) saw a large drop in short interest during the month of October. As of October 31st, there was short interest totalling 6,010,000 shares, a drop of 8.2% from the September 30th total of 6,550,000 shares. Currently, 1.6% of the shares of the company are sold short. Based on an average trading volume of 2,040,000 shares, the short-interest ratio is currently 2.9 days.
Shares of NYSE:VTR traded up $0.54 during trading on Monday, reaching $58.84. 27,906 shares of the company’s stock traded hands, compared to its average volume of 2,750,724. Ventas has a fifty-two week low of $56.52 and a fifty-two week high of $75.40. The company has a quick ratio of 0.72, a current ratio of 0.72 and a debt-to-equity ratio of 1.11. The firm has a market cap of $21.83 billion, a PE ratio of 14.46, a P/E/G ratio of 5.04 and a beta of 0.17. The company has a 50-day simple moving average of $68.47 and a 200-day simple moving average of $68.38.
Ventas (NYSE:VTR) last posted its earnings results on Friday, October 25th. The real estate investment trust reported $0.23 EPS for the quarter, missing the Zacks’ consensus estimate of $0.94 by ($0.71). Ventas had a net margin of 12.73% and a return on equity of 4.59%. The business had revenue of $983.16 million for the quarter, compared to analyst estimates of $935.43 million. During the same quarter last year, the business earned $0.99 earnings per share. Ventas’s revenue was up 5.0% on a year-over-year basis. On average, equities research analysts forecast that Ventas will post 3.84 EPS for the current year.
VTR has been the topic of several analyst reports. Stifel Nicolaus downgraded Ventas from a “buy” rating to a “hold” rating and cut their price target for the stock from $74.00 to $66.00 in a research report on Wednesday, October 30th. BMO Capital Markets cut their price target on Ventas to $63.00 and set a “market perform” rating on the stock in a research report on Friday, November 8th. Citigroup downgraded Ventas from a “buy” rating to a “neutral” rating and cut their price target for the stock from $76.00 to $67.00 in a research report on Monday, October 28th. ValuEngine downgraded Ventas from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Barclays initiated coverage on Ventas in a research report on Tuesday, September 3rd. They set an “equal weight” rating and a $74.00 price target on the stock. Two investment analysts have rated the stock with a sell rating and fourteen have assigned a hold rating to the company’s stock. Ventas presently has a consensus rating of “Hold” and a consensus price target of $66.58.
Large investors have recently bought and sold shares of the company. Citizens Financial Group Inc RI grew its position in shares of Ventas by 230.5% during the 3rd quarter. Citizens Financial Group Inc RI now owns 347 shares of the real estate investment trust’s stock valued at $25,000 after acquiring an additional 242 shares during the period. Kavar Capital Partners LLC acquired a new stake in shares of Ventas during the 2nd quarter valued at about $27,000. HM Payson & Co. acquired a new stake in shares of Ventas during the 2nd quarter valued at about $29,000. Gradient Investments LLC grew its position in shares of Ventas by 1,007.7% during the 2nd quarter. Gradient Investments LLC now owns 432 shares of the real estate investment trust’s stock valued at $30,000 after acquiring an additional 393 shares during the period. Finally, Optimum Investment Advisors grew its position in shares of Ventas by 77.1% during the 3rd quarter. Optimum Investment Advisors now owns 496 shares of the real estate investment trust’s stock valued at $36,000 after acquiring an additional 216 shares during the period. Hedge funds and other institutional investors own 88.22% of the company’s stock.
Ventas, Inc, an S&P 500 company, is a leading real estate investment trust. Its diverse portfolio of approximately 1,200 assets in the United States, Canada and the United Kingdom consists of seniors housing communities, medical office buildings, university-based research and innovation centers, inpatient rehabilitation and long-term acute care facilities, and health systems.
Read More: Using other technical indicators with support levels
Receive News & Ratings for Ventas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventas and related companies with MarketBeat.com's FREE daily email newsletter.